A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
09
2022
accepted:
01
02
2023
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
To evaluate the efficacy of a myopia control spectacle lens (DIMS) at slowing the progression of myopia in a population of European children in comparison with 0.01% atropine and combined DIMS and atropine. The study was a non-randomised experimenter-masked prospective controlled observational study of individuals aged 6-18 years with progressing myopia but no ocular pathology. Participants were allocated, according to patient/parent choice, to receive 0.01% atropine eyedrops, DIMS (Hoya® MiyoSmart®) spectacles, combined atropine+DIMS or single vision spectacle lenses (control group). The key outcome variables, cycloplegic autorefraction spherical equivalent refraction (SER) and axial length (AL), were measured at baseline and after three, six, and 12 months. Of the 146 participants (mean age 10.3y ±3.2), 53 received atropine, 30 DIMS spectacles, 31 atropine+DIMS, and 32 single vision control spectacles. Generalized linear mixed model analysis revealed for SER, whilst controlling for age and SER at baseline, at each stage all treatment groups had significantly reduced progression compared with the control group (p<0.016). For AL, whilst controlling for baseline age and AL, at 6 and 12 months all treatment groups had significantly less progression than the control group (p<0.005). For SER only, in pairwise comparisons at 12 months the atropine+DIMS group had significantly reduced progression compared with the DIMS only and Atropine only groups (p<0.001). In a European population, DIMS and atropine are effective at reducing myopia progression and axial elongation in progressing myopia and are most successful at reducing myopia progression when used in combination.
Identifiants
pubmed: 36795775
doi: 10.1371/journal.pone.0281816
pii: PONE-D-22-24122
pmc: PMC9934319
doi:
Substances chimiques
Atropine
7C0697DR9I
Types de publication
Controlled Clinical Trial
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0281816Informations de copyright
Copyright: © 2023 Nucci et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
PN has received honoraria from Hoya for lecturing, Hoya and Thea for attending meetings, and support from ANFAO. BE has received research funding, consultancy, and lecturing fees from Hoya. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
BMC Ophthalmol. 2019 May 9;19(1):106
pubmed: 31072389
Ophthalmology. 2019 Jan;126(1):113-124
pubmed: 30514630
Eye (Lond). 2020 Nov;34(11):2020-2028
pubmed: 32958872
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916204
Am J Ophthalmol. 2020 Mar;211:207-216
pubmed: 31837317
Bull World Health Organ. 2012 Oct 1;90(10):728-38
pubmed: 23109740
Br J Ophthalmol. 2022 Aug;106(8):1110-1114
pubmed: 33731364
Prog Retin Eye Res. 2021 Jul;83:100923
pubmed: 33253901
Nat Genet. 2020 Apr;52(4):401-407
pubmed: 32231278
Am J Ophthalmol. 1982 Jul;94(1):91-6
pubmed: 7091289
Ophthalmic Physiol Opt. 2020 Sep;40(5):549-556
pubmed: 32808381
Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M106-M131
pubmed: 30817829
Br J Ophthalmol. 2020 Mar;104(3):363-368
pubmed: 31142465
Eur J Epidemiol. 2015 Apr;30(4):305-15
pubmed: 25784363
Eye (Lond). 2014 Feb;28(2):142-6
pubmed: 24357836
Int Ophthalmol. 2021 Jun;41(6):2001-2008
pubmed: 33634343
Diseases. 2018 Sep 30;6(4):
pubmed: 30274355
Ophthalmic Physiol Opt. 2005 Sep;25(5):381-91
pubmed: 16101943
Am J Ophthalmol. 2014 Feb;157(2):451-457.e1
pubmed: 24315293
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
Eur J Epidemiol. 2013 Dec;28(12):973-80
pubmed: 24142238
Ophthalmology. 2021 Aug;128(8):1180-1187
pubmed: 33422558
Acta Ophthalmol. 2019 Dec;97(8):e1136-e1140
pubmed: 31197953
Ophthalmology. 2012 Feb;119(2):347-54
pubmed: 21963266
BMC Ophthalmol. 2020 Dec 7;20(1):478
pubmed: 33287746
Br J Ophthalmol. 2022 Aug;106(8):1171-1176
pubmed: 33811039
Lancet. 2008 Dec 20;372(9656):2152-61
pubmed: 19101391
Curr Eye Res. 2021 Aug;46(8):1223-1226
pubmed: 33460537
Transl Vis Sci Technol. 2020 Aug 05;9(9):11
pubmed: 32879767
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):49
pubmed: 32347918